Coherus Oncology Statistics
Total Valuation
CHRS has a market cap or net worth of $261.08 million. The enterprise value is $123.74 million.
Important Dates
The next estimated earnings date is Monday, March 9, 2026, after market close.
| Earnings Date | Mar 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CHRS has 120.87 million shares outstanding. The number of shares has increased by 2.22% in one year.
| Current Share Class | 120.87M |
| Shares Outstanding | 120.87M |
| Shares Change (YoY) | +2.22% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 6.59% |
| Owned by Institutions (%) | 46.20% |
| Float | 112.89M |
Valuation Ratios
The trailing PE ratio is 4.10.
| PE Ratio | 4.10 |
| Forward PE | n/a |
| PS Ratio | 0.90 |
| Forward PS | 3.08 |
| PB Ratio | 2.86 |
| P/TBV Ratio | 6.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 0.80 |
| EV / Sales | 0.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.24 |
| Quick Ratio | 1.19 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.34 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -10.26% |
| Return on Invested Capital (ROIC) | -89.73% |
| Return on Capital Employed (ROCE) | -58.14% |
| Weighted Average Cost of Capital (WACC) | 14.19% |
| Revenue Per Employee | $1.76M |
| Profits Per Employee | $980,829 |
| Employee Count | 158 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 4.88 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +77.05% in the last 52 weeks. The beta is 0.96, so CHRS's price volatility has been similar to the market average.
| Beta (5Y) | 0.96 |
| 52-Week Price Change | +77.05% |
| 50-Day Moving Average | 1.49 |
| 200-Day Moving Average | 1.23 |
| Relative Strength Index (RSI) | 61.95 |
| Average Volume (20 Days) | 3,350,509 |
Short Selling Information
The latest short interest is 29.74 million, so 24.60% of the outstanding shares have been sold short.
| Short Interest | 29.74M |
| Short Previous Month | 29.07M |
| Short % of Shares Out | 24.60% |
| Short % of Float | 26.34% |
| Short Ratio (days to cover) | 25.37 |
Income Statement
In the last 12 months, CHRS had revenue of $277.73 million and earned $154.97 million in profits. Earnings per share was $1.34.
| Revenue | 277.73M |
| Gross Profit | 156.38M |
| Operating Income | -83.85M |
| Pretax Income | 61.03M |
| Net Income | 154.97M |
| EBITDA | -79.79M |
| EBIT | -83.85M |
| Earnings Per Share (EPS) | $1.34 |
Full Income StatementBalance Sheet
The company has $191.66 million in cash and $54.32 million in debt, with a net cash position of $137.34 million or $1.14 per share.
| Cash & Cash Equivalents | 191.66M |
| Total Debt | 54.32M |
| Net Cash | 137.34M |
| Net Cash Per Share | $1.14 |
| Equity (Book Value) | 87.77M |
| Book Value Per Share | 0.76 |
| Working Capital | 88.66M |
Full Balance SheetCash Flow
| Operating Cash Flow | -90.19M |
| Capital Expenditures | n/a |
| Free Cash Flow | -90.19M |
| FCF Per Share | -$0.75 |
Full Cash Flow StatementMargins
Gross margin is 56.31%, with operating and profit margins of -30.19% and 55.80%.
| Gross Margin | 56.31% |
| Operating Margin | -30.19% |
| Pretax Margin | 21.98% |
| Profit Margin | 55.80% |
| EBITDA Margin | -28.73% |
| EBIT Margin | -30.19% |
| FCF Margin | n/a |
Dividends & Yields
CHRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.22% |
| Shareholder Yield | -2.22% |
| Earnings Yield | 59.36% |
| FCF Yield | -34.54% |
Analyst Forecast
The average price target for CHRS is $5.51, which is 155.09% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.51 |
| Price Target Difference | 155.09% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 5.82% |
| EPS Growth Forecast (5Y) | -9.96% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CHRS has an Altman Z-Score of -3.27 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.27 |
| Piotroski F-Score | 4 |
